dyslipidaemia
Cardiovascular · 2006–2007
4decisions
3medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| Nicotinic Acid use in combination with a HMG CoA reductase inhibitor (statin) in patients with dyslipidaemia with adequately controlled LDL-C and whose HDL-C levels are… | Mar 2007 | Recommended | no section in document |
| nicotinic acid Treatment of dyslipidaemia in patients with adequately controlled LDL cholesterol and inadequately controlled HDL cholesterol (HDL-C <1 mmol/L) despite… | Mar 2007 | Recommended | no section in document |
| rosuvastatin calcium For use in patients that meet the criteria set out in the General Statement for Lipid Lowering Drugs. Note: Doses higher than 20 mg per day should be used with… | Jul 2006 | Recommended with restriction | no section in document |
| amlodipine besylate with atorvastatin calcium Fixed combination for patients with concomitant hypertension and dyslipidaemia, or concomitant angina and dyslipidaemia, meeting criteria set out in the… | Jul 2006 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.